PharmaEssentia Corporation (TPE:6446)

Market Cap	348.59B +103.2%
Revenue (ttm)	17.50B +54.3%
Net Income	5.93B +52.1%
EPS	15.96 +51.8%
Shares Out	371.63M
PE Ratio	58.76
Forward PE	40.08
Dividend	1.10 (0.12%)
Ex-Dividend Date	Jul 9, 2026

Volume	2,504,784
Open	958.00
Previous Close	938.00
Day's Range	929.00 - 964.00
52-Week Range	438.85 - 978.00
Beta	0.43
Analysts	Buy
Price Target	778.83 (-16.88%)
Earnings Date	Aug 12, 2026

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and imm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 131
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6446

Financial Performance

In 2025, PharmaEssentia's revenue was 15.63 billion, an increase of 60.61% compared to the previous year's 9.73 billion. Earnings were 5.05 billion, an increase of 70.13%.

Analyst Summary

According to 6 analysts, the average rating for 6446 stock is "Buy." The 12-month stock price target is $778.83, which is a decrease of -16.88% from the latest price.

Price Target

$778.83

(-16.88% downside)

Analyst Consensus: Buy